Abel Hall LLC
MRNA icon

Abel Hall LLC’s Moderna MRNA Stock Holding History

Abel Hall LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$399K Buy
+2,073
New +$223K 0.07% 297

Other funds holding MRNA

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Abel Hall LLC's MRNA Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Moderna (MRNA) in Q3 2026: 2,073 shares worth $399K. The stake represents 0.07% of the portfolio and ranks #297 among its holdings.

493 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Abel Hall LLC held 2,073 shares of Moderna worth $399K as of Q3 2026.
  • Moderna was a new Abel Hall LLC position in Q3 2026.
  • Moderna made up 0.07% of Abel Hall LLC's portfolio in Q3 2026, its #297 holding.
  • 493 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.